Observe Medical ASA (the "Company") has on November 11, 2022, granted 1,000,000
share options in the Company to the group CEO, Rune Nystad.

The options have been granted with an exercise price of NOK 4.5 per option
share. The options will west in three tranches, whereby each tranche comprising
1/3 of the options will vest on the first, second and third anniversary of the
grant date, respectively.

The options have been granted without consideration and each option will upon
exercise give the right to acquire one share in the Company. Any shares acquired
upon exercise will be subject to a 12 months' lock-up period from the date
received by the option holder, and all options will expire and lapse if not
exercised within 11 November  2026.

Please refer to the attached notification of trading for further details.

This information is subject to the disclosure requirements in Regulation EU
596/2014 (MAR) article 19 number 3 and section 5-12 of the Norwegian Securities
Trading Act.

This stock exchange announcement was published by Per Arne Nygård, CFO, on
November 11, 2022 at CET 09:35.